Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Prolia and osteonecrosis?What is dabrafenib mesylate msn patent issue?Mebendazole ingredients?How does paclitaxel's binding to albumin change its pharmacokinetics?How often should lurbinectedin's long term effects be monitored?
See the DrugPatentWatch profile for solriamfetol
Solriamfetol (brand name Sunosi) was first approved by the U.S. Food and Drug Administration (FDA) in 2019 for treating excessive daytime sleepiness in people with obstructive sleep apnea (OSA) or narcolepsy. [1]
FDA approval in 2019 is the key starting point for “how long it’s been around” in clinical use in the U.S. [1]
The provided sources only state the FDA approval year (2019). [1]
At approval, it was indicated to treat excessive daytime sleepiness in adults with: - Obstructive sleep apnea (OSA) - Narcolepsy [1]
From the 2019 FDA approval to today (2026), solriamfetol has been available in the U.S. for about 7 years. [1] Sources: [1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202022
Other Questions About Solriamfetol :